A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer

NCT00183807

Last updated date
Study Location
U.S.C. / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Esophageal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must have clinically documented unresectable or metastatic esophageal cancer and histologic confirmation of the diagnosis with tumor. To be unresectable a patient must have been examined by a surgeon and declared unresectable.

- Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed.

- Patients must agree to have a sample 20 cc drawn in addition to routine labs with each cycle of chemotherapy.

- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan. If prior radiation therapy was administered, measurable disease must be outside the radiation field.

- Patients may have received prior adjuvant chemotherapy; this must have been completed at least 6 months prior to the initiation of therapy for metastatic disease.

- Patients must have a Zubrod performance status of 0-2.

- Patients must have a predicted life expectancy of at least 12 weeks.

- Patients must have a pre-treatment granulocyte count (i.e., segmented neutrophils + bands) of >1,500/mm3, a hemoglobin level of greater than or equal to9.0 gm/dl, and a platelet count of >100,000/mm3.

- Patients must have adequate renal function as documented by

1) creatinine less than or equal to 1.5 X institutional upper limit of normal OR 2) creatinine clearance > 60 mL/min as calculated with

- Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2x the institutional upper limit of normal, regardless of whether patients have liver involvement secondary to tumor. Aspartate transaminase (SGOT) must be less than or equal to 3x institutional upper limit of normal, unless the liver is involved with tumor, in which case the aspartate transaminase must be less than or equal to 5x institutional upper limit of normal.

- No major surgery within 1 month of starting study drug.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who have received prior therapy with CPT-11 or cisplatin as adjuvant therapy
less than 12 months prior to initiation of therapy for metastatic disease. All other
adjuvant chemotherapy must have been completed at least 6 months prior to entry onto
trial.


- Prior treatment with celebrex, that is if patients are currently using celebrex on a
regular basis for the treatment of other disorders, i.e arthritis, etc.


- Patients who have received prior treatment for metastatic or unresectable disease


- Patients taking full-dose NSAIDs, including aspirin, regularly for any reason (e.g.,
arthritis, history of TIA or myocardial infarction). Patients taking cardiac
preventive dose ASA (<81mg daily) are eligible. Patients should stop taking any other
NSAIDs 14 days prior to receiving first dose of Celecoxib.


- Patients may not have a history of an allergy to sulfonamide drugs.


- Patients may not have active peptic ulcer disease or other contraindications to
chronic NSAID use or aspirin use.


- Patients may not have known lactose intolerance.


- Patients with any active or uncontrolled infection, including known HIV infection


- Patients with psychiatric disorders that would interfere with consent or follow-up


- Patients with a history of myocardial infarction within the previous six months or
congestive heart failure requiring therapy Pregnant or lactating women. Men and women
of reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.


- Presence of clinically apparent central nervous system metastases or carcinomatous
meningitis


- Patients with a history of seizures are ineligible. Patients receiving phenytoin,
phenobarbital, or other anti-epileptic prophylaxis are ineligible.


- Patients with uncontrolled diabetes mellitus, defined as random blood sugar greater
than or equal to 200 mg/dl.


- Patients with any other severe concurrent disease, which in the judgment of the
investigator, would make the patient inappropriate for entry into this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Esophageal CancerSunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
NCT00702884
  1. Columbus, Ohio
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Esophageal CancerCelecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
NCT00066716
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Esophageal CancerCombination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00381706
  1. Norwalk, Connecticut
  2. Lewes, Delaware
  3. Newark, Delaware
  4. Washington, District of Columbia
  5. Aurora, Illinois
  6. Bloomington, Illinois
  7. Canton, Illinois
  8. Carthage, Illinois
  9. Chicago, Illinois
  10. Decatur, Illinois
  11. Eureka, Illinois
  12. Evanston, Illinois
  13. Galesburg, Illinois
  14. Galesburg, Illinois
  15. Harvey, Illinois
  16. Havana, Illinois
  17. Hopedale, Illinois
  18. Joliet, Illinois
  19. Macomb, Illinois
  20. Normal, Illinois
  21. Normal, Illinois
  22. Ottawa, Illinois
  23. Ottawa, Illinois
  24. Pekin, Illinois
  25. Peoria, Illinois
  26. Peoria, Illinois
  27. Peoria, Illinois
  28. Peoria, Illinois
  29. Peoria, Illinois
  30. Peru, Illinois
  31. Princeton, Illinois
  32. Rockford, Illinois
  33. Spring Valley, Illinois
  34. Springfield, Illinois
  35. Urbana, Illinois
  36. Urbana, Illinois
  37. Elkhart, Indiana
  38. Fort Wayne, Indiana
  39. Indianapolis, Indiana
  40. Indianapolis, Indiana
  41. Kokomo, Indiana
  42. La Porte, Indiana
  43. Michigan City, Indiana
  44. South Bend, Indiana
  45. South Bend, Indiana
  46. South Bend, Indiana
  47. South Bend, Indiana
  48. Ames, Iowa
  49. Bettendorf, Iowa
  50. Cedar Rapids, Iowa
  51. Cedar Rapids, Iowa
  52. Des Moines, Iowa
  53. Des Moines, Iowa
  54. Des Moines, Iowa
  55. Des Moines, Iowa
  56. Des Moines, Iowa
  57. Des Moines, Iowa
  58. Des Moines, Iowa
  59. Iowa City, Iowa
  60. Mason City, Iowa
  61. Ottumwa, Iowa
  62. Sioux City, Iowa
  63. Sioux City, Iowa
  64. Sioux City, Iowa
  65. West Des Moines, Iowa
  66. Anthony, Kansas
  67. Chanute, Kansas
  68. Dodge City, Kansas
  69. El Dorado, Kansas
  70. Fort Scott, Kansas
  71. Independence, Kansas
  72. Kingman, Kansas
  73. Lawrence, Kansas
  74. Liberal, Kansas
  75. Newton, Kansas
  76. Overland Park, Kansas
  77. Parsons, Kansas
  78. Pratt, Kansas
  79. Salina, Kansas
  80. Shawnee Mission, Kansas
  81. Wellington, Kansas
  82. Wichita, Kansas
  83. Wichita, Kansas
  84. Wichita, Kansas
  85. Wichita, Kansas
  86. Wichita, Kansas
  87. Winfield, Kansas
  88. Bangor, Maine
  89. Baltimore, Maryland
  90. Easton, Maryland
  91. Elkton MD, Maryland
  92. Boston, Massachusetts
  93. Boston, Massachusetts
  94. Boston, Massachusetts
  95. Burlington, Massachusetts
  96. South Weymouth, Massachusetts
  97. Springfield, Massachusetts
  98. Ann Arbor, Michigan
  99. Ann Arbor, Michigan
  100. Dearborn, Michigan
  101. Escanaba, Michigan
  102. Flint, Michigan
  103. Flint, Michigan
  104. Grosse Pointe Woods, Michigan
  105. Iron Mountain, Michigan
  106. Jackson, Michigan
  107. Kalamazoo, Michigan
  108. Kalamazoo, Michigan
  109. Kalamazoo, Michigan
  110. Lansing, Michigan
  111. Livonia, Michigan
  112. Pontiac, Michigan
  113. Port Huron, Michigan
  114. Saginaw, Michigan
  115. Saint Joseph, Michigan
  116. St. Joseph, Michigan
  117. Warren, Michigan
  118. Burnsville, Minnesota
  119. Coon Rapids, Minnesota
  120. Duluth, Minnesota
  121. Duluth, Minnesota
  122. Duluth, Minnesota
  123. Edina, Minnesota
  124. Fridley, Minnesota
  125. Hutchinson, Minnesota
  126. Lichfield, Minnesota
  127. Maplewood, Minnesota
  128. Maplewood, Minnesota
  129. Minneapolis, Minnesota
  130. Minneapolis, Minnesota
  131. Minneapolis, Minnesota
  132. Robbinsdale, Minnesota
  133. Saint Louis Park, Minnesota
  134. Saint Louis Park, Minnesota
  135. Saint Paul, Minnesota
  136. Shakopee, Minnesota
  137. St. Paul, Minnesota
  138. Waconia, Minnesota
  139. Woodbury, Minnesota
  140. Independence, Missouri
  141. Kansas City, Missouri
  142. Kansas City, Missouri
  143. Kansas City, Missouri
  144. Kansas City, Missouri
  145. Kansas City, Missouri
  146. Kansas City, Missouri
  147. Kansas City, Missouri
  148. Liberty, Missouri
  149. Saint Joseph, Missouri
  150. Saint Louis, Missouri
  151. Saint Louis, Missouri
  152. Omaha, Nebraska
  153. Omaha, Nebraska
  154. Omaha, Nebraska
  155. Omaha, Nebraska
  156. Omaha, Nebraska
  157. Las Vegas, Nevada
  158. Las Vegas, Nevada
  159. Lebanon, New Hampshire
  160. Marlton, New Jersey
  161. Newark, New Jersey
  162. Sparta, New Jersey
  163. Voorhees, New Jersey
  164. Voorhees, New Jersey
  165. Bronx, New York
  166. Buffalo, New York
  167. East Syracuse, New York
  168. Glens Falls, New York
  169. New York, New York
  170. New York, New York
  171. Chapel Hill, North Carolina
  172. Charlotte, North Carolina
  173. Goldsboro, North Carolina
  174. Hendersonville, North Carolina
  175. Kinston, North Carolina
  176. Akron, Ohio
  177. Canton, Ohio
  178. Cleveland, Ohio
  179. Columbus, Ohio
  180. Lima, Ohio
  181. Allentown, Pennsylvania
  182. Bethlehem, Pennsylvania
  183. Danville, Pennsylvania
  184. East Stroudsburg, Pennsylvania
  185. Hazleton, Pennsylvania
  186. Hershey, Pennsylvania
  187. Lewistown, Pennsylvania
  188. Philadelphia, Pennsylvania
  189. Philadelphia, Pennsylvania
  190. Philadelphia, Pennsylvania
  191. Philadelphia, Pennsylvania
  192. Philadelphia, Pennsylvania
  193. Scranton, Pennsylvania
  194. State College, Pennsylvania
  195. State College, Pennsylvania
  196. Wilkes-Barre, Pennsylvania
  197. Wilkes-Barre, Pennsylvania
  198. Williamsport, Pennsylvania
  199. Florence, South Carolina
  200. Sioux Falls, South Dakota
  201. Sioux Falls, South Dakota
  202. Sioux Falls, South Dakota
  203. Kingsport, Tennessee
  204. Temple, Texas
  205. Berlin, Vermont
  206. Burlington, Vermont
  207. Danville, Virginia
  208. Norton, Virginia
  209. Eau Claire, Wisconsin
  210. Eau Claire, Wisconsin
  211. Green Bay, Wisconsin
  212. Green Bay, Wisconsin
  213. Green Bay, Wisconsin
  214. Green Bay, Wisconsin
  215. Marinette, Wisconsin
  216. Marshfield, Wisconsin
  217. Milwaukee, Wisconsin
  218. Minocqua, Wisconsin
  219. Oconto Falls, Wisconsin
  220. Rhinelander, Wisconsin
  221. Rice Lake, Wisconsin
  222. Stevens Point, Wisconsin
  223. Sturgeon Bay, Wisconsin
  224. Wausau, Wisconsin
  225. Wausau, Wisconsin
  226. Weston, Wisconsin
  227. Wisconsin Rapids, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Esophageal CancerSutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
NCT00400114
  1. Ottawa, Ontario
  2. Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Official Title  ICMJE A Phase II Study of Irinotecan (Camptosar), Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Brief Summary This study is for patients with cancer of the esophagus. This study uses the drugs irinotecan, cisplatin and celecoxib. Irinotecan (also known as CPT-11) was recently approved by the U.S. Food and Drug Administration (FDA) for use in colon cancer, but has not been approved by the FDA for use in the treatment of cancers of the esophagus. Cisplatin is a drug that is commonly used to treat patients with cancer of the esophagus. We are combining these two chemotherapy drugs with a drug called Celebrex. Celebrex (also called Celecoxib) is an oral medication that is approved by the FDA for pain in the treatment of arthritis. There is some information to suggest that this drug may have anti-cancer activity. In prior studies combining irinotecan and cisplatin, tumors of the esophagus have been shown to shrink. We are adding Celebrex to these drugs to see if it makes the drugs work better to shrink cancer or cause fewer side effects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Esophageal Cancer
Intervention  ICMJE Drug: irinotecan, cisplatin, celecoxib
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 20, 2014)
6
Original Enrollment  ICMJE
 (submitted: September 9, 2005)
65
Actual Study Completion Date  ICMJE March 2008
Actual Primary Completion Date February 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have clinically documented unresectable or metastatic esophageal cancer and histologic confirmation of the diagnosis with tumor. To be unresectable a patient must have been examined by a surgeon and declared unresectable.
  • Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed.
  • Patients must agree to have a sample 20 cc drawn in addition to routine labs with each cycle of chemotherapy.
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan. If prior radiation therapy was administered, measurable disease must be outside the radiation field.
  • Patients may have received prior adjuvant chemotherapy; this must have been completed at least 6 months prior to the initiation of therapy for metastatic disease.
  • Patients must have a Zubrod performance status of 0-2.
  • Patients must have a predicted life expectancy of at least 12 weeks.
  • Patients must have a pre-treatment granulocyte count (i.e., segmented neutrophils + bands) of >1,500/mm3, a hemoglobin level of greater than or equal to9.0 gm/dl, and a platelet count of >100,000/mm3.
  • Patients must have adequate renal function as documented by

    1) creatinine less than or equal to 1.5 X institutional upper limit of normal OR 2) creatinine clearance > 60 mL/min as calculated with

  • Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2x the institutional upper limit of normal, regardless of whether patients have liver involvement secondary to tumor. Aspartate transaminase (SGOT) must be less than or equal to 3x institutional upper limit of normal, unless the liver is involved with tumor, in which case the aspartate transaminase must be less than or equal to 5x institutional upper limit of normal.
  • No major surgery within 1 month of starting study drug.

Exclusion Criteria:

  • Patients who have received prior therapy with CPT-11 or cisplatin as adjuvant therapy less than 12 months prior to initiation of therapy for metastatic disease. All other adjuvant chemotherapy must have been completed at least 6 months prior to entry onto trial.
  • Prior treatment with celebrex, that is if patients are currently using celebrex on a regular basis for the treatment of other disorders, i.e arthritis, etc.
  • Patients who have received prior treatment for metastatic or unresectable disease
  • Patients taking full-dose NSAIDs, including aspirin, regularly for any reason (e.g., arthritis, history of TIA or myocardial infarction). Patients taking cardiac preventive dose ASA (<81mg daily) are eligible. Patients should stop taking any other NSAIDs 14 days prior to receiving first dose of Celecoxib.
  • Patients may not have a history of an allergy to sulfonamide drugs.
  • Patients may not have active peptic ulcer disease or other contraindications to chronic NSAID use or aspirin use.
  • Patients may not have known lactose intolerance.
  • Patients with any active or uncontrolled infection, including known HIV infection
  • Patients with psychiatric disorders that would interfere with consent or follow-up
  • Patients with a history of myocardial infarction within the previous six months or congestive heart failure requiring therapy Pregnant or lactating women. Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
  • Presence of clinically apparent central nervous system metastases or carcinomatous meningitis
  • Patients with a history of seizures are ineligible. Patients receiving phenytoin, phenobarbital, or other anti-epileptic prophylaxis are ineligible.
  • Patients with uncontrolled diabetes mellitus, defined as random blood sugar greater than or equal to 200 mg/dl.
  • Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00183807
Other Study ID Numbers  ICMJE 3E-02-1
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Southern California
Study Sponsor  ICMJE University of Southern California
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Syma Iqbal, M.D.U.S.C./ Norris Comprehensive Cancer Center
PRS Account University of Southern California
Verification Date May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP